577 related articles for article (PubMed ID: 26796110)
21. Undetected lymph node metastases in presumed early stage NSCLC SABR patients.
Cerra-Franco A; Diab K; Lautenschlaeger T
Expert Rev Anticancer Ther; 2016 Aug; 16(8):869-75. PubMed ID: 27279087
[TBL] [Abstract][Full Text] [Related]
22. The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy - a nationwide cohort study.
de Ruiter JC; van der Noort V; van Diessen JNA; Smit EF; Damhuis RAM; Hartemink KJ;
Lung Cancer; 2024 May; 191():107792. PubMed ID: 38621343
[TBL] [Abstract][Full Text] [Related]
23. The management of stage I Non-Small cell lung cancer (NSCLC) in Ontario: A Population-Based study of patterns of care and Stereotactic Ablative Body radiotherapy (SABR) utilization from 2010 to 2019.
Ashworth A; Kong W; Owen T; Hanna TP; Brundage M
Radiother Oncol; 2024 May; 194():110153. PubMed ID: 38364940
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort.
Soldà F; Lodge M; Ashley S; Whitington A; Goldstraw P; Brada M
Radiother Oncol; 2013 Oct; 109(1):1-7. PubMed ID: 24128806
[TBL] [Abstract][Full Text] [Related]
25. Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial.
Palma DA; Chen H; Bahig H; Gaede S; Harrow S; Laba JM; Qu XM; Rodrigues GB; Yaremko BP; Yu E; Louie AV; Dhaliwal I; Ryerson CJ
BMC Cancer; 2019 Dec; 19(1):1206. PubMed ID: 31829203
[TBL] [Abstract][Full Text] [Related]
26. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
[TBL] [Abstract][Full Text] [Related]
27. A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis.
Chiang A; Thibault I; Warner A; Rodrigues G; Palma D; Soliman H; Jain S; Poon I; Cheung P
Radiother Oncol; 2016 Mar; 118(3):478-84. PubMed ID: 26795773
[TBL] [Abstract][Full Text] [Related]
28. The use of texture-based radiomics CT analysis to predict outcomes in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy.
Starkov P; Aguilera TA; Golden DI; Shultz DB; Trakul N; Maxim PG; Le QT; Loo BW; Diehn M; Depeursinge A; Rubin DL
Br J Radiol; 2019 Feb; 92(1094):20180228. PubMed ID: 30457885
[TBL] [Abstract][Full Text] [Related]
29. Stereotactic ablative radiotherapy (SABR) for non-small cell lung cancer.
Iyengar P; Westover K; Timmerman RD
Semin Respir Crit Care Med; 2013 Dec; 34(6):845-54. PubMed ID: 24258574
[TBL] [Abstract][Full Text] [Related]
30. A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer.
Murray P; Franks K; Hanna GG
Br J Radiol; 2017 Mar; 90(1071):20160732. PubMed ID: 27885858
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease.
Verstegen NE; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
Radiother Oncol; 2011 Nov; 101(2):250-4. PubMed ID: 22056535
[TBL] [Abstract][Full Text] [Related]
32. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned.
Chang JY; Bezjak A; Mornex F;
J Thorac Oncol; 2015 Apr; 10(4):577-85. PubMed ID: 25514807
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.
Chang JY; Lin SH; Dong W; Liao Z; Gandhi SJ; Gay CM; Zhang J; Chun SG; Elamin YY; Fossella FV; Blumenschein G; Cascone T; Le X; Pozadzides JV; Tsao A; Verma V; Welsh JW; Chen AB; Altan M; Mehran RJ; Vaporciyan AA; Swisher SG; Balter PA; Fujimoto J; Wistuba II; Feng L; Lee JJ; Heymach JV
Lancet; 2023 Sep; 402(10405):871-881. PubMed ID: 37478883
[TBL] [Abstract][Full Text] [Related]
35. Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly.
Shinde A; Li R; Kim J; Salgia R; Hurria A; Amini A
Semin Oncol; 2018 Aug; 45(4):210-219. PubMed ID: 30286944
[TBL] [Abstract][Full Text] [Related]
36. Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer: A Systematic Review.
Chen H; Louie AV; Boldt RG; Rodrigues GB; Palma DA; Senan S
Clin Lung Cancer; 2016 Sep; 17(5):e141-e149. PubMed ID: 26791542
[TBL] [Abstract][Full Text] [Related]
37. Metabolic tumour volume is prognostic in patients with non-small-cell lung cancer treated with stereotactic ablative radiotherapy.
Dosani M; Yang R; McLay M; Wilson D; Liu M; Yong-Hing CJ; Hamm J; Lund CR; Olson R; Schellenberg D
Curr Oncol; 2019 Feb; 26(1):e57-e63. PubMed ID: 30853810
[TBL] [Abstract][Full Text] [Related]
38. Stereotactic ablative radiotherapy in treatment of early-stage non-small cell lung cancer: Unsolved questions and frontiers ahead.
Zhang J; Kong L; Jiao Q; Li M; Yu J
Cancer Lett; 2017 Aug; 401():46-52. PubMed ID: 28526616
[TBL] [Abstract][Full Text] [Related]
39. Impact of Lung Parenchymal-Only Failure on Overall Survival in Early-Stage Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy.
Elbanna M; Shiue K; Edwards D; Cerra-Franco A; Agrawal N; Hinton J; Mereniuk T; Huang C; Ryan JL; Smith J; Aaron VD; Burney H; Zang Y; Holmes J; Langer M; Zellars R; Lautenschlaeger T
Clin Lung Cancer; 2021 May; 22(3):e342-e359. PubMed ID: 32736936
[TBL] [Abstract][Full Text] [Related]
40. Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: Comparing survival outcomes in adenocarcinoma and squamous cell carcinoma.
Abel S; Hasan S; White R; Schumacher L; Finley G; Colonias A; Wegner RE
Lung Cancer; 2019 Feb; 128():127-133. PubMed ID: 30642444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
